Dr. Heymach on the Significance of Nivolumab for Lung Cancer
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.
The long-term follow-up for nivolumab is important for the field, states Heymach. Overall, patients in the CheckMate-026 trial saw an improvement in survival of a few months.
The long-term data informs researchers that there are some patients that are still benefitting from the treatment years later, explains Heymach.
